Brittany Cote

Articles

Talati Highlights “Game-Changing” Potential of Venetoclax/HMA Combos for Elderly AML

September 8th 2020

Chetasi Talati, MD, discusses early results from a multicenter chart review examining treatment patterns and outcomes of patients with newly diagnosed AML who received venetoclax/HMA combinations in the real-world setting and the next phase of the ongoing research initiative.

Adjuvant Endocrine Therapy Boosts Survival in Small, HR+, ERBB2- Breast Cancer

September 3rd 2020

Adjuvant endocrine therapy was found to be associated with improved overall survival in patients with hormone receptor–positive, ERBB2-negative, node-negative breast cancer with small but invasive tumors.

Later-Line Treatment Approaches Make Headway in CRC Management

September 2nd 2020

Axel Grothey, MD, explains the impact of tumor sidedness on treatment decisions and highlights novel later-line approaches that are under examination in colorectal cancer.

Venetoclax Plus Azacitidine Significantly Prolongs OS, Incidence of Remission in AML

September 1st 2020

Venetoclax plus azacitidine led to a statistically significant prolongation of overall survival with a higher incidence of remission in treatment-naïve older patients with acute myeloid leukemia.

Chemotherapy Infrequently Used in High-Risk Sarcoma, Despite Proven Benefit

August 31st 2020

The overall use of chemotherapy in high-risk soft tissue sarcomas has been found to be significantly low.

Hill Highlights the Potential of Selinexor as a Less Intensive Option for DLBCL

August 31st 2020

Brian T. Hill, MD, PhD, sheds light on XPO1 as a target in diffuse large B-cell lymphoma, the emergence of selinexor in the treatment landscape, and exciting agents in the pipeline.

Daratumumab Plus CyBorD Poised to Change Frontline AL Amyloidosis Care

August 30th 2020

Sandy Wong, MD, discusses the ANDROMEDA trial, the need for further investigation of venetoclax, and research with anti-amyloid fibril drugs in light chain amyloidosis.

Rucaparib Shows Meaningful Antitumor Activity in BRCA1/2-Mutated mCRPC

August 28th 2020

Rucaparib (Rubraca) demonstrated encouraging antitumor activity with a manageable safety profile in patients with BRCA-mutant metastatic castration-resistant prostate cancer.

CAR T-Cell Therapies Continue to Raise the Bar in Lymphoma Management

August 27th 2020

Pashna N. Munshi, MD, discusses the CAR T-cell therapies that have emerged in the lymphoma space and highlights the next steps for research with these products.

Personalized Approach Is Needed for Transplant-Ineligible Multiple Myeloma

August 27th 2020

Smith Giri, MD, MHS, discusses the options available for transplant-ineligible patients with myeloma, the factors to consider to personalize treatment, and future directions in the field.

Moore Highlights Hope for Mirvetuximab Soravtansine in FRα-High Ovarian Cancer

August 25th 2020

In an interview with OncLive, Kathleen Moore, MD, discusses the MIRASOL trial and the hope for mirvetuximab soravtansine in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high FRα expression.

RCC Care Continues to Evolve as the COVID-19 Crisis Rages On

August 21st 2020

Toni K. Choueiri, MD, discusses the novel coronavirus disease, which continues to impact the care of patients with metastatic renal cell carcinoma and other cancers in a multitude of ways.

Novel Combinations Dominate Later-Line Metastatic CRC Treatment Landscape

August 20th 2020

Thorvardur (Thor) Halfdanarson, MD, discusses novel approaches under investigation in the later-line treatment of patients with CRC.

Research Efforts Abound in HER2-Positive Gastric and GEJ Cancers

August 19th 2020

Rutika J. Mehta, MD, MPH discusses key updates in gastric and gastroesophageal junction management, trials of interest, and the importance of testing for biomarkers.

Taking a Tiered Approach to Prostate Cancer Surgery During the COVID-19 Pandemic

August 18th 2020

Quoc-Dien Trinh, MD, discusses the impact of the COVID-19 pandemic on prostate cancer treatment and factors that are considered to inform treatment decisions.

Immunotherapies Continue to Show Intriguing Benefit in Cisplatin-Ineligible Metastatic Urothelial Cancer

August 17th 2020

Guru P. Sonpavde, MD, discusses several trials in the field of first-line metastatic urothelial cancer that are testing combinations with gemcitabine/platinum-based therapy followed by maintenance avelumab.

Late LHRH Agonists Injections Cause Spike in Testosterone Levels in Prostate Cancer

August 17th 2020

Luteinizing hormone-releasing hormone agonists were found to often be administered later than the scheduled dosing used in patients with prostate cancer on pivotal clinical trials, leading to late testosterone values being greater than 20 ng/dL and the mean testosterone level almost doubling castration level.

Alternative Splicing, E7107 Compound Could Aid in Prostate Cancer Pathogenesis and Drug Development

August 17th 2020

In prostate cancer, investigators have revealed a link between disease progression and the severity of splicing dysregulation, as well as establishing intron retention as an indicator of prostate cancer stemness and aggressiveness.

MCL Treatment Armamentarium Transforms With BTK Inhibitors, CAR T-Cell Addition

August 13th 2020

Peter Martin, MD, provides an overview of what the current MCL treatment paradigm looks like as well as areas of future exploration and debate.

AST-008 Plus PD-1 Blockade Shows Early Synergy in Merkel Cell Carcinoma, CSCC

August 12th 2020

Mohammed M. Milhem, MBBS, discusses the promise of the AST-008 combination in patients with Merkel cell carcinoma and CSCC who do not achieve a response with PD-1 inhibitors alone.